CRISPR Therapeutics AG
COMPOSITIONS AND METHODS FOR GENE EDITING BY TARGETING FIBRINOGEN-ALPHA

Last updated:

Abstract:

Provided include compositions, methods, and systems for modulating the expression, function, and/or activity of a target gene, for example a blood-clotting protein such as Factor VIII (FVIII), in a cell by genome editing. Also provided include compositions, methods, and systems for treating a subject having or suspected of having a disorder or health condition, e.g., hemophilia A, employing ex vivo and/or in vivo genome editing.

Status:
Application
Type:

Utility

Filling date:

15 Feb 2019

Issue date:

6 May 2021